In fact, results of several immunotherapy trials have shown that it is possible to use different antigen vectors to trigger an efficient T cells response to tumor associate antigens such as CEA, MUC-1, k-ras/mut in mCRC patients [13]. This evidence concerns the gene CEACAM5 and neoplasm.